Ryan Bushey
Digital Editor

Ryan Bushey is a digital editor for Advantage Business Media’s Science Group.  He covers scientific discoveries, emerging technologies and the business of the life sciences sector for R&D Magazine and Drug Discovery & Development along with managing social media for both publications. He’s an experienced journalist whose work has appeared in Business Insider, Slate, and Indiewire.

Overall, the drug was able to improve patients’ conditions and helped more individuals become seizure-free than placebo.
Digital Editor
|
5.25.2017
10:12am
The trial is supported by the HIV Vaccines Trial Network (HVTN) and the National Institute of Allergy and Infectious Diseases (NIAID).
Digital Editor
|
5.25.2017
10:11am
An experimental osteoporosis drug being developed by Amgen and UCB produced surprising safety data in this evaluation.
Digital Editor
|
5.22.2017
11:16am
Investigators gave 125 patients 150 or 300 mg subcutaneously administered dosages every four weeks or 300 mg every two weeks.
Digital Editor
|
5.19.2017
11:11am
The healthcare giant’s pharmaceutical unit intends to launch or file for regulatory approval more than 10 novel therapies with blockbuster potential between...
Digital Editor
|
5.17.2017
10:40am
Advertisement
Scott Gottlieb was a physician-turned-health consultant who previously served as deputy commissioner of the FDA under the George W. Bush administration.
Digital Editor
|
5.16.2017
11:12am
The company will pay $120 million to Remedy Pharmaceuticals, the original developer of the drug.
Digital Editor
|
5.15.2017
11:19am
The report showed growth in spending on medicines rose less than half the rate of the previous two years.
Digital Editor
|
5.12.2017
12:09pm
Galcanezumab is a monoclonal antibody designed to target a protein linked to pain signaling called calcitonin gene related peptide (CGRP).
Digital Editor
|
5.12.2017
12:04pm
Avelumab previously gained approval from the FDA for merkel cell carcinoma.
Digital Editor
|
5.11.2017
10:55am
The French pharmaceutical giant's efforts are similar to the programs launched by Merck and Johnson & Johnson earlier this year.
Digital Editor
|
5.10.2017
10:34am
The life-saving allergy treatment may still be potent for up to four years after their printed expiration dates.
Digital Editor
|
5.9.2017
11:30am
The FDA made their decision after reviewing trial data analyzing the drug’s efficacy.
Digital Editor
|
5.8.2017
9:06am
Advertisement
One million people diagnosed with this condition could soon have some relief.
Digital Editor
|
5.5.2017
11:15am
The National Institutes of Health (NIH) has gained a funding boost under a new congressional spending bill.
Digital Editor
|
5.4.2017
8:51am
The Food and Drug Administration granted new indications to Stivarga and Rydapt.
Digital Editor
|
5.1.2017
9:02am
Both companies hope this drug can be a viable candidate in the competitive PCSK9 inhibitor market.
Digital Editor
|
4.26.2017
10:42am
Gilenya is an oral disease modifying therapy aimed at controlling disease activity in relapse-remitting multiple sclerosis.
Digital Editor
|
4.26.2017
9:04am
The announcements focused on Tecfidera, Tysabri, and Spinraza.
Digital Editor
|
4.25.2017
8:33am
Bristol-Myers Squibb presented the new data at the International Liver Congress being held in Amsterdam.
Digital Editor
|
4.24.2017
8:29am
Two experiments were performed to verify decarboxylative borylation’s efficacy.
Digital Editor
|
4.21.2017
9:02am
Advertisement
AbbVie reported its experimental cancer drug failed to meet primary endpoints in two different phase 3 studies.
Digital Editor
|
4.20.2017
10:55am
The largest pharmacy benefit manager in the U.S. released a report in March showcasing prescription spending and coverage for 2016.
Digital Editor
|
4.19.2017
9:10am
Two new studies indicate the first signs of a possible treatment approach for both SCA2 and ALS.
Digital Editor
|
4.18.2017
8:00am
Bristol-Myers Squibb is reducing its portfolio by licensing two experimental assets to other companies.
Digital Editor
|
4.13.2017
9:41am
The Woburn, Massachusetts-based startup is getting closer to launching a novel drug engineered to treat chronic noise-induced hearing loss.
Digital Editor
|
4.11.2017
9:51am
The FDA made the decision based on the results from two open label-clinical trials.
Digital Editor
|
4.10.2017
8:33am
The FDA made its decision to give this designation after reviewing data from a Phase 2 study.
Digital Editor
|
4.7.2017
9:24am
The project received $1.8 billion in funding after the passage of the 21st Century Act in December 2016.
Digital Editor
|
4.5.2017
12:03pm
Investigators running this randomized, double-blind trial enrolled with 945 patients diagnosed with unresectable stage III or stage IV melanoma.
Digital Editor
|
4.4.2017
12:01pm
Patients participating in this trial, named HERACLES, had these RAS-wild type tumors that were HER2-positive and refractory to all available treatment options.
Digital Editor
|
4.3.2017
12:30pm
Patients diagnosed with multiple sclerosis will soon be able to access a new treatment option.
Digital Editor
|
3.29.2017
9:55am
A new analysis for heart failure drug Entresto revealed novel insights for managing diabetes when compared to an older medication.
Digital Editor
|
3.28.2017
9:08am
One area targeted for drastic downsizing is agencies performing government-funded science research, including the National Institutes of Health (NIH).
Digital Editor
|
3.22.2017
10:24am
These late-stage study results were presented in Washington D.C. at the annual American College of Cardiology meeting.
Digital Editor
|
3.20.2017
10:28am
An experimental treatment for clostridium dificile infections is getting a second chance.
Digital Editor
|
3.17.2017
8:50am
The project, called the Asthma Mobile Health Study, launched in March 2015.
Digital Editor
|
3.16.2017
9:50am
The financing will help Spero Therapeutics further advance its assets into the different stages of clinical testing.
Digital Editor
|
3.16.2017
9:44am
The company will work with Editas Medicine, a biotech backed by Bill Gates and Google.
Digital Editor
|
3.15.2017
10:45am